Hollow Brook Wealth Management LLC Purchases 34,001 Shares of Pfizer Inc. $PFE

Posted by Francis Steltz on Jun 16th, 2026

Hollow Brook Wealth Management LLC grew its position in Pfizer Inc. (NYSE:PFE – Free Report) by 24.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,152 shares of the biopharmaceutical company’s stock after purchasing an additional 34,001 shares during the quarter. Pfizer makes up approximately 1.1% of Hollow Brook Wealth Management LLC’s portfolio, making the stock its 25th largest holding. Hollow Brook Wealth Management LLC’s holdings in Pfizer were worth $4,336,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Triad Wealth Partners LLC grew its stake in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the last quarter. ETF Store Inc. grew its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares during the last quarter. Mattern Wealth Management LLC grew its stake in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares during the last quarter. Pines Wealth Management LLC grew its stake in shares of Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares during the last quarter. Finally, Pathway Financial Advisers LLC grew its stake in shares of Pfizer by 0.9% in the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 403 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.82.

View Our Latest Stock Report on Pfizer

Pfizer Stock Down 0.8%

PFE opened at $26.01 on Tuesday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm’s fifty day moving average price is $26.38 and its two-hundred day moving average price is $26.33. The company has a market capitalization of $148.24 billion, a P/E ratio of 19.86 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the company earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s payout ratio is presently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s obesity drug berobenatide posted encouraging Phase 2b results, with favorable tolerability and proof-of-concept data that could strengthen the company’s late-stage pipeline. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
Positive Sentiment: Pfizer has been upgraded by RBC Capital, reinforcing optimism around the stock’s valuation and income appeal. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
Positive Sentiment: The CEO said Pfizer could eventually get back to high-single-digit growth, suggesting the business may be better positioned than some investors expect. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
Neutral Sentiment: Multiple research and analyst roundups focused on Pfizer’s growth drivers, challenges, and recent stock performance, keeping the stock in the spotlight but without a major new catalyst. Top Research Reports for Pfizer & Newmont Corp.
Neutral Sentiment: Pfizer was among the most searched stocks on Zacks, reflecting investor curiosity around what comes next for the name. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Neutral Sentiment: Coverage on Pfizer’s discounted valuation weighed the downside from fading COVID revenue and patent cliffs against upside from oncology, new products, and pipeline execution. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.